How PMHA Alliance is Informing Psychedelic Policy – A Conversation with Jared Moffat of New Approach

As the movement to expand access to psychedelic-assisted therapy (PAT) gains momentum, state-level policy will determine whether these treatments become integrated into mainstream healthcare or remain out of reach for those who need them most. At PMHA Alliance, we understand that well-informed policy is essential for ensuring equitable access, and that decisions must be guided by data, not just advocacy. That’s why we are committed to curating and providing a robust, evidence-based library of insights, research, and real-world data to policymakers, Medicaid administrators, and other key stakeholders. By equipping decision-makers with the critical information they need, we help shape policies that prioritize accessibility, safety, and effectiveness. To dive deeper into this evolving landscape, we spoke with Jared Moffat, Policy Director for New Approach, about the organization’s 2025 priorities, its role in shaping legislation in New Jersey, and the impact of Senate Bill 219 in New Mexico.

Building Evidence to Shape Policy: New Approach’s 2025 Priorities

As psychedelic-assisted therapy continues to evolve, New Approach is focused on advancing state-supported research and generating real-world evidence to guide policymakers, public health officials, and Medicaid administrators.

“In such a complex field, collaboration with leading organizations like PMHA Alliance is essential,” Moffat said. “PMHA and New Approach are working together to support research initiatives that can optimize care models and generate data to demonstrate the impact of PAT on public health.”

By engaging with lawmakers and state agencies, New Approach is working to establish policies that balance safety, accessibility, and innovation, particularly in states where interest in psychedelic therapy is growing, such as New Jersey and New Mexico.

Shaping the Future of Psychedelic-Assisted Therapy in New Jersey

New Approach has been leading the legislative effort in New Jersey, where policymakers and public health leaders are increasingly recognizing the potential of psychedelic-assisted therapy.

“Key leaders in the state, including the Department of Health, have expressed interest in developing a pilot research program that prioritizes a community-focused, health equity model for PAT,” Moffat said. “With local allies—including researchers and community-based organizations—New Approach and PMHA are working together to build support and pave the way for implementation once this legislation is approved.”

By focusing on inclusive, community-driven approaches, the goal is to design a research-backed, accessible framework for psychedelic-assisted care in New Jersey that could serve as a model for other states. By taking this approach PMHA is ensuring that philanthropic dollars are strongly leveraged to get state governments to back further research.

Senate Bill 219: A Milestone for PAT in New Mexico

New Mexico is emerging as another key state in the movement to expand psychedelic-assisted therapy, with Senate Bill 219 (SB 219) playing a pivotal role in shaping PAT access.

“SB 219 is a thoughtful and responsible proposal that advances psilocybin research while establishing a regulated program for patients with qualifying conditions,” Moffat explained. “The legislation was developed with input from a broad group of experts in New Mexico, including the New Mexico Department of Health.”

One of the bill’s most innovative features is the creation of a Patient Equity Fund—a groundbreaking initiative designed to help patients cover the costs of psychedelic-assisted therapy.

“If enacted, this bill will complement ongoing efforts led by PMHA and local allies, including the development of a community-based pilot program in partnership with Dr. Larry Leeman at the University of New Mexico,” Moffat added.

By integrating research, policy, and community engagement, SB 219 represents a significant step toward ensuring equitable access to psychedelic-assisted therapy, serving as a model for other states seeking to implement similar programs.

The Road Ahead for Psychedelic Policy

New Approach continues to collaborate with advocacy organizations, policymakers, and public health experts to expand access to psychedelic-assisted therapy while ensuring policies are evidence-based and equitable.

“We’re working with policymakers and advocacy coalitions across the country to create legal pathways for psychedelic-assisted therapy that prioritize public health, research, and access,” Moffat said. “It’s about making sure these therapies are not just legal, but that they are affordable, accessible, and implemented responsibly.”

About Jared

Jared Moffat is the Policy Director for New Approach. He and other members of the team have years of experience leading successful efforts to advance criminal justice reform and public health policy initiatives at the state level. He is currently working with policymakers and advocacy coalitions across the country to expand access to psychedelic-assisted therapy and shape responsible legislation.